FDA Approved: LYUMJEV — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for LYUMJEV (insulin lispro-aabc) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Lyumjev (insulin lispro)

Snippet

SUPPL AP for LYUMJEV (INSULIN LISPRO-AABC)